Cryo-Cell International, Inc.

NYSE American CCEL

Cryo-Cell International, Inc. EBT Margin for the Trailing 12 Months (TTM) ending August 31, 2024: -38.78%

Cryo-Cell International, Inc. EBT Margin is -38.78% for the Trailing 12 Months (TTM) ending August 31, 2024, a -472.52% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Cryo-Cell International, Inc. EBT Margin for the Trailing 12 Months (TTM) ending August 31, 2023 was 10.41%, a 114.16% change year over year.
Cryo-Cell International, Inc. EBT Margin for the Trailing 12 Months (TTM) ending August 31, 2022 was 4.86%, a -75.11% change year over year.
Cryo-Cell International, Inc. EBT Margin for the Trailing 12 Months (TTM) ending August 31, 2021 was 19.53%, a 37.05% change year over year.
Cryo-Cell International, Inc. EBT Margin for the Trailing 12 Months (TTM) ending August 31, 2020 was 14.25%, a 26.94% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NYSE American: CCEL

Cryo-Cell International, Inc.

CEO	Mr. David I. Portnoy
IPO Date	April 4, 1994
Location	United States
Headquarters	700 Brooker Creek Boulevard
Employees	82
Sector	Healthcare
Industries Biotechnology 3D Printing Baby & Childcare Containers & Packaging Frozen Foods Medical Instruments Personal Care Plastics

Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Key trends

Past 5 years